The present invention provides a method and a pharmaceutical composition for the treatment of the NDO comprising the viral expression vector carrying a transcription cassette that harbors transgene(s) inhibiting/silencing neurotransmission or synaptic transmission of afferent neurons.

The present invention relates to a composition for alleviating or treating pain. A pharmaceutical composition of the present invention contains two or more selected from the group consisting of GAD, IL-10, and a gene encoding GDNF. The pharmaceutical composition of the present invention exhibits an excellent analgesic effect at a dosage lower than that of individual administration since genes are coadministered, and thus conventional side effects and toxicity can be reduced. Therefore, the pharmaceutical composition of the present invention can be useful in alleviating or treating pain.

This document describes biochemical pathways for producing 4-hydroxybutyrate, 4-aminobutyrate, putrescine or 1,4-butanediol by forming one or two terminal functional groups, comprised of amine or hydroxyl group, in a C5 backbone substrate such as 2-oxoglutarate or L-glutamate.

Methods and materials for the biosynthesis of compounds involved in glutamate metabolism, and derivatives and compounds related thereto are provided. Also provided are products produced in accordance with these methods and materials.

The present invention relates to application of a novel signal peptide in L-glutamate and its derivatives production from konjac powder, which belongs to the field of gene engineering, enzyme engineering and metabolism engineering. The signal peptide which mediated secretion of -mannanase was invented, and the recombinant strain with this signal peptide had advantages on utilizing konjac powder to produce related products, and its utilization efficiency of konjac powder, production efficiency, and yield were higher than other signal peptides. The recombinant strain possessing this new signal peptide had advantages on utilizing cheaper konjac powder as substrate to lower the process costs on L-glutamic acid and its high-value-added products.

The invention relates to a preparation method of green nylon poly butyrolactams, the biological materials of GABA in vacuum under the condition of high temperature melt decomposition and purified butyrolactams, then by vacuum polymerization of green nylon poly butyrolactams. Compared with the prior art, the invention is prepared by biological method for the synthesis of a wide range of sources, to solve the problem of raw material supply PA4 for mass production, reduce the cost of reaction, and the reaction condition is simple, easy to implement simplified synthesis steps, from the laboratory to the transformation of industrial production.

The present disclosure provides antigen presenting polypeptide comprising a TGF-? MOD that is reversibly masked and acts as a TGF-? receptor agonist. The antigen presenting polypeptides comprising one or more chemical conjugation sites for incorporation of, for example, Type 1 Diabetes (T1D) associated epitope containing polypeptides. The antigen-presenting polypeptides and their T1D-associated epitope conjugates are useful for modulating the activity of a T-cell, and accordingly, the present disclosure provides methods of modulating activity of a T-cell in vitro and in vivo as a method of treatment of T1D.

A method for delivery of a therapeutic agent to a nervous tissue. In particular, a method of delivering a therapeutic agent to a nervous tissue protected by the brain-blood barrier or meninges is disclosed. The method for delivery allows delivery of a therapeutic agent to a nervous tissue with high efficiency. In addition, the delivery method of a therapeutic agent to a nervous tissue is safe since it has lower side effects such as nervous damage than a method of administering a therapeutic agent directly to a nervous tissue.

The present invention provides a method and a pharmaceutical composition for the treatment of the NDO comprising the viral expression vector carrying a transcription cassette that harbors transgene(s) inhibiting/silencing neurotransmission or synaptic transmission of afferent neurons.

The present disclosure provides T-cell modulatory multimeric polypeptides (TMMPs) comprising a type 1 diabetes (T1D)-associated peptide epitope, MHC class II polypeptides, and PD-L1 polypeptides. A TMMP of the present disclosure is useful for modulating activity of a T cell. Thus, the present disclosure provides compositions and methods for modulating the activity of T cells, as well as compositions and methods for treating persons who have T1D.